CHEST 2023

Deji Adegunsoye, MD, PhD, FCCP, reviewed the role of genetic testing in pulmonary fibrosis in the past, present, and future management of the disease.

Diego J. Maselli, MD, FCCP, and other experts provided updates on biologics approved in asthma and in trials for COPD.

Before leaving Honolulu, make plans with your colleagues to reconvene for CHEST 2024, October 6-9, in Boston, MA.

Lisa Moores, MD, FCCP, helped guide audience members through a case study of intermediate-risk pulmonary embolism that involved various choices for risk stratification and therapy.

Panelists, including Max Hockstein, MD, MS, provided an overview of the available tools for determining the etiology of shock and their real-world usage.

A Wednesday morning session, chaired by Thomas DeCato, MD, FCCP, will help clinicians navigate the current guidance for pulmonary function tests, address controversial issues, and answer unresolved questions from their daily practice.

A Wednesday morning panel discussion, chaired by Sean Callahan, MD, will help attendees distinguish incidental interstitial lung abnormalities from more consequential findings such as interstitial lung disease.

Listen now for a preview of the day from Chair of the Scientific Program Committee, Aneesa Das, MD, FCCP, and her guest, Chair of CHEST 2024, Gabriel T. Bosslet, MD, FCCP.

A Wednesday morning discussion session co-chaired by Kathryn Pendleton, MD, FCCP, will look at the current problems and opportunities with the use of artificial intelligence to identify patients with sepsis or predict the onset of sepsis.

George Z. Cheng, MD, PhD, FCCP, will chair a debate that will explore the need for improved safety and efficacy data, lessons that can be learned from other disciplines, and pitfalls that might be avoided.